Replimune Begin Period Cash Flow Over Time
| REPL Stock | USD 12.26 0.53 4.14% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Replimune Performance and Replimune Correlation. Replimune |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Begin Period Cash Flow Analysis
Compare Replimune Group and related stocks such as Nuvalent, Ventyx Biosciences, and Ascendis Pharma AS Begin Period Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NUVL | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 3 M | 10.3 M | 68.5 M | 241.8 M | 253.9 M |
| VTYX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 309 K | 244 K | 70.8 M | 64.8 M | 68.1 M |
| ASND | 15.7 M | 15.7 M | 15.7 M | 14.5 M | 19.4 M | 50.2 M | 119.6 M | 180.3 M | 195.4 M | 277.9 M | 598.1 M | 584.5 M | 446.3 M | 444.8 M | 270.1 M |
| UTHR | 5 M | 252.2 M | 162.7 M | 154 M | 284.3 M | 397.7 M | 831.8 M | 1 B | 705.1 M | 669.2 M | 738.4 M | 738.7 M | 894.8 M | 961.2 M | 1 B |
| LYRA | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 24.2 M | 10.1 M | 74.9 M | 46.1 M | 33.9 M | 35 M |
| KRON | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 10.2 M | 32.6 M | 250 M | 200.3 M | 78 M | 105 M |
| GOSS | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 315 K | 105.4 M | 135.1 M | 486.6 M | 183.5 M | 112 M | 140.7 M |
| KURA | 11.1 K | (11.5 K) | 27.5 K | 6 K | 6.6 K | 1.1 M | 15.4 M | 9.7 M | 11.4 M | 16.1 M | 26.1 M | 325.7 M | 90.9 M | 51.8 M | 43.1 M |
| PTGX | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 9.3 M | 4.1 M | 21.1 M | 106.5 M | 82.7 M | 33.5 M | 117.8 M | 123.9 M | 126 M | 69.7 M |
| MRUS | 8 M | 8 M | 8 M | 8 M | 12.9 M | 1.7 M | 34.5 M | 68.3 M | 171.2 M | 164.7 M | 197.8 M | 163.3 M | 241.7 M | 148.4 M | 121.3 M |
| AVTE | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.5 M | 4.6 M | 54.2 M | 22.4 M | 19.5 M |
| KROS | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 23.4 M | 7.1 M | 266 M | 231.4 M | 280.4 M | 149.1 M |
| SNDX | 3.6 M | 3.6 M | 3.6 M | 537 K | 10.1 M | 10 M | 23.2 M | 23.8 M | 35.4 M | 34 M | 24.7 M | 115.4 M | 222.1 M | 74.5 M | 52.9 M |
| MLYS | 42 K | 42 K | 42 K | 42 K | 42 K | 42 K | 42 K | 42 K | 42 K | 42 K | 42 K | 1.4 M | 10.7 M | 87.7 M | 92.1 M |
| CRNX | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 12.2 M | 14.2 M | 45.5 M | 40.8 M | 93.6 M | 201.2 M | 34 M | 63.1 M |
| NAMS | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 7.9 M | 53.1 M | 467.7 M | 491.1 M |
| PRTC | 11.3 M | 11.3 M | 11.3 M | 10.9 M | 7.2 M | 62 M | 134.8 M | 63 M | 72.6 M | 117.1 M | 132.4 M | 403.9 M | 465.7 M | 149.9 M | 149.5 M |
Replimune Group and related stocks such as Nuvalent, Ventyx Biosciences, and Ascendis Pharma AS Begin Period Cash Flow description
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.My Equities
My Current Equities and Potential Positions
| Replimune Group | REPL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 12.26
Check out Replimune Performance and Replimune Correlation. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Replimune technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.